{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:09:03Z","timestamp":1787062143936,"version":"build-2736575974"},"reference-count":34,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Immunotherapy-based combinations have shown promising survival benefits in patients with hepatocellular carcinoma (HCC) included in clinical trials. However, real-world data are needed to assess the effectiveness and safety of these therapies in diverse clinical settings and regions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>We conducted a Brazilian multicenter observational study, including 163 patients with unresectable or metastatic HCC treated with immunotherapy between August 2020 and March 2024 in 14 centers. Patient characteristics, treatment outcomes, and adverse events were analyzed. Survival outcomes were assessed using the Kaplan-Meier method, and Cox regression identified predictors of survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Most patients were male (85.3%), with a median age of 72 years. Liver cirrhosis was present in 70.6%, and 77% had Barcelona Clinic Liver Cancer stage C. Immunotherapy was predominantly first-line (91.4%), with atezolizumab plus bevacizumab as the most common regimen (77.9%). The median treatment duration was 4.9 months, and the median overall survival (OS) was 14.7 months (95% CI, 11.6 to 24.5), with 12- and 24-month survival rates of 57.0% and 41.4%, respectively. Considering the patients with Child-Pugh A and performance status 0-1 (n = 116), the median OS was 20.6 months (95% CI, 12.4 to 25.8). Immune-related adverse events occurred in 19.6%, mainly thyroid disorders and skin manifestations. Adverse events related to bevacizumab included variceal (n = 6) and other bleeding events (n = 7). Albumin-bilirubin grade 2 to 3, metabolic dysfunction\u2013associated steatotic liver disease, and esophagogastric varices were independently associated with reduced OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>In a real-world setting, immunotherapy-based treatments demonstrated effectiveness and safety profiles consistent with clinical trials, although survival was influenced by liver function, etiology, and baseline variceal status. These findings highlight the relevance of baseline liver disease characteristics in guiding immunotherapy in HCC and underscore the need for tailored management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/go-25-00128","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T19:59:08Z","timestamp":1753905548000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness and Safety of Immunotherapy for Hepatocellular Carcinoma in Clinical Practice: A Brazilian Multicenter Study"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0216-3618","authenticated-orcid":true,"given":"Leonardo Gomes","family":"da Fonseca","sequence":"first","affiliation":[{"name":"Oncologia D\u2019Or and Instituto D\u2019Or de Pesquisa e Ensino, S\u00e3o Paulo, Brazil"},{"name":"Instituto do Cancer do Estado de S\u00e3o Paulo, University of S\u00e3o Paulo School of Medicine, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cec\u00edlia Souza","family":"Freire","sequence":"additional","affiliation":[{"name":"Oncologia D\u2019Or and Instituto D\u2019Or de Pesquisa e Ensino, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0446-4998","authenticated-orcid":true,"given":"Rodrigo Antonio Vieira","family":"Guedes","sequence":"additional","affiliation":[{"name":"Oncologia D\u2019Or and Instituto D\u2019Or de Pesquisa e Ensino, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Castro","family":"Lyra","sequence":"additional","affiliation":[{"name":"Oncologia D\u2019Or and Instituto D\u2019Or de Pesquisa e Ensino, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6366-8786","authenticated-orcid":true,"given":"Maria Ignez Freitas Melro","family":"Braguiroli","sequence":"additional","affiliation":[{"name":"Oncologia D\u2019Or and Instituto D\u2019Or de Pesquisa e Ensino, S\u00e3o Paulo, Brazil"},{"name":"Instituto do Cancer do Estado de S\u00e3o Paulo, University of S\u00e3o Paulo School of Medicine, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Bruno","family":"Siqueira","sequence":"additional","affiliation":[{"name":"Oncologia D\u2019Or and Instituto D\u2019Or de Pesquisa e Ensino, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria De Lourdes Lopes","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"Oncologia D\u2019Or and Instituto D\u2019Or de Pesquisa e Ensino, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9666-4237","authenticated-orcid":true,"given":"Alexandre de Mendon\u00e7a","family":"Palladino","sequence":"additional","affiliation":[{"name":"Oncologia D\u2019Or and Instituto D\u2019Or de Pesquisa e Ensino, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Luiz","family":"Najman","sequence":"additional","affiliation":[{"name":"Oncologia D\u2019Or and Instituto D\u2019Or de Pesquisa e Ensino, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Tancredi","sequence":"additional","affiliation":[{"name":"Oncologia D\u2019Or and Instituto D\u2019Or de Pesquisa e Ensino, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-1891","authenticated-orcid":true,"given":"Duilio Reis","family":"Da Rocha Filho","sequence":"additional","affiliation":[{"name":"Oncologia D\u2019Or and Instituto D\u2019Or de Pesquisa e Ensino, S\u00e3o Paulo, Brazil"},{"name":"Hospital Universit\u00e1rio Walter Cant\u00eddio, Universidade Federal do Ceara Fortaleza, CE, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1269-4567","authenticated-orcid":true,"given":"Markus Cavalcante","family":"Gifoni","sequence":"additional","affiliation":[{"name":"Oncologia D\u2019Or and Instituto D\u2019Or de Pesquisa e Ensino, S\u00e3o Paulo, Brazil"},{"name":"Universidade Federal da Bahia, Salvador, BA, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Luiz Stelko","family":"Pereira","sequence":"additional","affiliation":[{"name":"Oncologia D\u2019Or and Instituto D\u2019Or de Pesquisa e Ensino, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela Crosara Alves","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Oncologia D\u2019Or and Instituto D\u2019Or de Pesquisa e Ensino, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucila Soares Da Silva","family":"Rocha","sequence":"additional","affiliation":[{"name":"Oncologia D\u2019Or and Instituto D\u2019Or de Pesquisa e Ensino, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimundo","family":"Paran\u00e1","sequence":"additional","affiliation":[{"name":"Oncologia D\u2019Or and Instituto D\u2019Or de Pesquisa e Ensino, S\u00e3o Paulo, Brazil"},{"name":"Universidade Federal da Bahia, Salvador, BA, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0065-2194","authenticated-orcid":true,"given":"Paulo Marcelo","family":"Hoff","sequence":"additional","affiliation":[{"name":"Oncologia D\u2019Or and Instituto D\u2019Or de Pesquisa e Ensino, S\u00e3o Paulo, Brazil"},{"name":"Instituto do Cancer do Estado de S\u00e3o Paulo, University of S\u00e3o Paulo School of Medicine, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.08.021"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1564"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4008"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.08.024"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18037"},{"key":"e_1_3_5_10_2","article-title":"Survival of trial-like and non\u2013trial-like patients with immunotherapy in advanced hepatocellular carcinoma in real world: A collaborative multicenter Indian study (IMHEP)","author":"Ramaswamy A","unstructured":"Ramaswamy A, Kulkarni A, John G, et al: Survival of trial-like and non\u2013trial-like patients with immunotherapy in advanced hepatocellular carcinoma in real world: A collaborative multicenter Indian study (IMHEP). JCO Glob Oncol 10.1200\/GO.23.00215","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S492881"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae142"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071722"},{"key":"e_1_3_5_14_2","article-title":"Brazilian landscape of hepatocellular carcinoma","author":"Fonseca LG","unstructured":"Fonseca LG, Chen ATC, de Oliveira IS, et al: Brazilian landscape of hepatocellular carcinoma. JCO Glob Oncol 10.1200\/GO.22.00416","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000466"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.9151"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800600817"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_5_22_2","unstructured":"Cancer Institute N: Common Terminology criteria for adverse events (CTCAE) common Terminology criteria for adverse events (CTCAE) v5.0. 2017"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0179-x"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16162878"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.5009\/gnl240085"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.005"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1159\/000529996"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-3399561"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0264-5"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143483"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03362-0"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1159\/000535839"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.10.040"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32468"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.22.27633"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-25-00128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T19:59:09Z","timestamp":1753905549000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-25-00128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1200\/GO-25-00128"],"URL":"https:\/\/doi.org\/10.1200\/go-25-00128","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2025-03-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500128"}}